Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B

Study Year Country Group n M/F Age(yr)(mean ±SD)
Sun LJ et al. [14] 2009 China Test 130 104/26 N/A
Cont. 130 104/26 N/A
Cui YL et al. [15] 2010 China Test 34 3/31 39.35 ± 10.61
Cont. 37 6/31 41.03 ± 11.48
Mi Lj et al. [16] 2009 China Test 30 30/712 38.4 ± 2.5
Cont. 28 24/3 38.3 ± 2.4
Zhang P [17] 2008 China Test 48 38/10 47 ± 15.8
Cont. 44 36/8 48 ± 16.2
Han YH et al. [18] 2007 China Test 58 36/22 N/A
Cont. 48 29/19 N/A
Yang DH et al. [19] 2004 China Test 30 N/A N/A
Cont. 41 N/A N/A
He Y et al. [20] 2005 China Test 13 11/2 38.2
Cont. 24 21/3 37.8
Liao JH et al. [21] 2004 China Test 36 29/7 39.5 ± 17.6
Cont. 40 32/8 38.6 ± 16.8
Yuan J et al. [22] 2001 China Test 20 17/3 35.1 ± 11.6
Cont. 20 20/0 34.8 ± 8.5
Zhang LQ et al. [23] 2006 China Test 29 24/5 N/A
Cont. 20 18/2 N/A
Zhan GQ et al. [24] 2006 China Test 62 N/A N/A
Cont. 36 N/A N/A
Cao L et al.[25] 2007 China Test 45 N/A N/A
Cont. 46 N/A N/A
Zhu GL et al. [26] 2002 China Test 31 25/6 N/A
Cont. 31 23/8 N/A
Zhou BX et al. [27] 2011 China Test 21 16/5 37.2
Cont. 21 15/6 38.1
Guo JC et al. [28] 2002 China Test 24 24/0 38 ± 17.1
Cont. 24 24/0 39 ± 18.4
Zhong YB et al. [29] 2007 China Test 24 20/4 29.2 ± 16.8
Cont. 35 29/6 33.8 ± 18.7
Zhou XX et al. [30] 2007 China Test 17 14/3 N/A
Cont. 18 15/3 N/A
Ding FY et al. [31] 2003 China Test 38 31/7 N/A
Cont. 38 33/5 N/A
Pan JZ et al. [32] 2007 China Test 40 N/A N/A
Cont. 42 N/A N/A
Wang Y et al. [33] 2003 China Test 30 N/A N/A
Cont. 30 N/A N/A
Qin SJ et al. [34] 2003 China Test 20 N/A N/A
  Cont. 15 N/A N/A